Biosimilars ‘Policy Salad’ Setting Back Sector, Canadian Study Says
Biosimilar Use Across Canada Remains Low
The Ontario Drug Policy Research Network has released a new study on biosimilar uptake across Canada, where the use of biosimilars is relatively low in comparison to other OECD countries.
You may also be interested in...
Citizens enrolled on Nova Scotia’s Pharmacare programs have 12 months to switch to biosimilar versions of certain biologic drugs, including some insulins and medications used to treat Crohn’s disease and rheumatoid arthritis.
A joint position statement published by originator-backed bodies the Canadian Association of Gastroenterology and Crohn’s and Colitis Canada has expressed caution over so-called ‘non-medical switching’ of IBD patients from brand biologics to biosimilars.
Canadian provinces must consider the impact of inflation on generic drugs during the next round of off-patent price setting, says a study from Aviseo and the Canadian Generic Pharmaceutical Association.